Compared to untreated cells, myeloid DCs from DMF-treated MS patients showed an immature phenotype, decreased expression of RelB, limited capacity to activate T cells and reduced secretion of pro-inflammatory cytokines IFN-γ, IL-17 and GM-CSF [176]. This evidence concerns the gene IFNG and myeloid sarcoma.